BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 23212204)

  • 1. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
    Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
    Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab in the therapy of uveitis in childhood.
    Biester S; Deuter C; Michels H; Haefner R; Kuemmerle-Deschner J; Doycheva D; Zierhut M
    Br J Ophthalmol; 2007 Mar; 91(3):319-24. PubMed ID: 17035274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
    Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
    Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
    Bawazeer A; Raffa LH; Nizamuddin SH
    Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab and adalimumab for uveitis.
    Martel JN; Esterberg E; Nagpal A; Acharya NR
    Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
    Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
    Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
    Petropoulos IK; Vaudaux JD; Guex-Crosier Y
    Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal adalimumab for refractory uveitis-related macular edema.
    Androudi S; Tsironi E; Kalogeropoulos C; Theodoridou A; Brazitikos P
    Ophthalmology; 2010 Aug; 117(8):1612-6. PubMed ID: 20378179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab therapy for refractory uveitis: a pilot study.
    Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL; Fraunfelder FW; Rosenbaum JT
    Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
    Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
    Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM
    Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.